{"title":"麻醉之外:氯胺酮在慢性疼痛和精神疾病中的作用越来越大。","authors":"Christopher Zaki","doi":"10.31083/JIN26766","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This review explores ketamine's expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders.</p><p><strong>Methods: </strong>A systematic search of PubMed, Cochrane Library, and Scopus databases identified studies on ketamine's efficacy and safety in chronic pain and psychiatric disorders. The analysis included randomized controlled trials (RCTs), observational studies, and systematic reviews.</p><p><strong>Results: </strong>Ketamine has demonstrated significant efficacy in managing chronic pain in neuropathic pain, fibromyalgia, and complex regional pain syndrome (CRPS), especially in treatment-resistant cases. Mental health comorbidities are common in chronic pain populations, with up to 50% experiencing depression or anxiety. Ketamine's N-methyl-D-aspartate (NMDA) receptor antagonism not only underlies its analgesic effects but also contributes to rapid antidepressant responses in treatment-resistant depression (TRD) and acute suicidal ideation, as evidenced by its FDA-approved formulation, Spravato (esketamine). Beyond depression, emerging evidence supports ketamine's potential use in anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain substance use disorders. However, its psychomimetic effects, safety concerns, and unclear long-term impact warrant careful clinical oversight.</p><p><strong>Conclusion: </strong>Ketamine presents a versatile therapeutic strategy for managing chronic pain and a wide range of mental health disorders, signifying its potential to bridge the gap in treatment-resistant cases. Ongoing research is needed to optimize dosing strategies, assess long-term safety, and integrate ketamine into multidisciplinary care models. This approach emphasizes personalized patient care and comprehensive monitoring to navigate the complexities of coexisting chronic pain and mental health challenges.</p>","PeriodicalId":16160,"journal":{"name":"Journal of integrative neuroscience","volume":"24 7","pages":"26766"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond Anesthesia: Ketamine's Expanding Role in Chronic Pain and Psychiatric Disorders.\",\"authors\":\"Christopher Zaki\",\"doi\":\"10.31083/JIN26766\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This review explores ketamine's expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders.</p><p><strong>Methods: </strong>A systematic search of PubMed, Cochrane Library, and Scopus databases identified studies on ketamine's efficacy and safety in chronic pain and psychiatric disorders. The analysis included randomized controlled trials (RCTs), observational studies, and systematic reviews.</p><p><strong>Results: </strong>Ketamine has demonstrated significant efficacy in managing chronic pain in neuropathic pain, fibromyalgia, and complex regional pain syndrome (CRPS), especially in treatment-resistant cases. Mental health comorbidities are common in chronic pain populations, with up to 50% experiencing depression or anxiety. Ketamine's N-methyl-D-aspartate (NMDA) receptor antagonism not only underlies its analgesic effects but also contributes to rapid antidepressant responses in treatment-resistant depression (TRD) and acute suicidal ideation, as evidenced by its FDA-approved formulation, Spravato (esketamine). Beyond depression, emerging evidence supports ketamine's potential use in anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain substance use disorders. However, its psychomimetic effects, safety concerns, and unclear long-term impact warrant careful clinical oversight.</p><p><strong>Conclusion: </strong>Ketamine presents a versatile therapeutic strategy for managing chronic pain and a wide range of mental health disorders, signifying its potential to bridge the gap in treatment-resistant cases. Ongoing research is needed to optimize dosing strategies, assess long-term safety, and integrate ketamine into multidisciplinary care models. This approach emphasizes personalized patient care and comprehensive monitoring to navigate the complexities of coexisting chronic pain and mental health challenges.</p>\",\"PeriodicalId\":16160,\"journal\":{\"name\":\"Journal of integrative neuroscience\",\"volume\":\"24 7\",\"pages\":\"26766\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of integrative neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/JIN26766\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of integrative neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/JIN26766","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
目的:综述氯胺酮在慢性疼痛和精神疾病治疗中的作用,重点介绍其药理机制、临床应用和治疗潜力。我们评估了其镇痛特性,fda批准的Spravato (es氯胺酮)用于抑郁症,以及标签外用于镇痛和精神疾病。方法:系统检索PubMed、Cochrane Library和Scopus数据库,确定氯胺酮治疗慢性疼痛和精神疾病的有效性和安全性研究。分析包括随机对照试验(rct)、观察性研究和系统评价。结果:氯胺酮对神经性疼痛、纤维肌痛和复杂区域疼痛综合征(CRPS)的慢性疼痛有显著的疗效,特别是对治疗难治性病例。精神健康合并症在慢性疼痛人群中很常见,高达50%的人患有抑郁或焦虑。氯胺酮的n -甲基- d -天冬氨酸(NMDA)受体拮抗性不仅是其镇痛作用的基础,而且有助于治疗难治疗性抑郁症(TRD)和急性自杀念头的快速抗抑郁反应,其fda批准的制剂Spravato (esketamine)证明了这一点。除了抑郁症,新出现的证据支持氯胺酮在焦虑症、强迫症、创伤后应激障碍和某些物质使用障碍方面的潜在用途。然而,它的精神模拟效应、安全问题和不明确的长期影响需要仔细的临床监督。结论:氯胺酮是一种多用途的治疗策略,用于治疗慢性疼痛和各种精神健康障碍,这表明它有潜力弥合治疗抵抗病例的差距。正在进行的研究需要优化剂量策略,评估长期安全性,并将氯胺酮纳入多学科护理模式。这种方法强调个性化的病人护理和全面的监测,以导航共存的慢性疼痛和心理健康挑战的复杂性。
Beyond Anesthesia: Ketamine's Expanding Role in Chronic Pain and Psychiatric Disorders.
Objective: This review explores ketamine's expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders.
Methods: A systematic search of PubMed, Cochrane Library, and Scopus databases identified studies on ketamine's efficacy and safety in chronic pain and psychiatric disorders. The analysis included randomized controlled trials (RCTs), observational studies, and systematic reviews.
Results: Ketamine has demonstrated significant efficacy in managing chronic pain in neuropathic pain, fibromyalgia, and complex regional pain syndrome (CRPS), especially in treatment-resistant cases. Mental health comorbidities are common in chronic pain populations, with up to 50% experiencing depression or anxiety. Ketamine's N-methyl-D-aspartate (NMDA) receptor antagonism not only underlies its analgesic effects but also contributes to rapid antidepressant responses in treatment-resistant depression (TRD) and acute suicidal ideation, as evidenced by its FDA-approved formulation, Spravato (esketamine). Beyond depression, emerging evidence supports ketamine's potential use in anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain substance use disorders. However, its psychomimetic effects, safety concerns, and unclear long-term impact warrant careful clinical oversight.
Conclusion: Ketamine presents a versatile therapeutic strategy for managing chronic pain and a wide range of mental health disorders, signifying its potential to bridge the gap in treatment-resistant cases. Ongoing research is needed to optimize dosing strategies, assess long-term safety, and integrate ketamine into multidisciplinary care models. This approach emphasizes personalized patient care and comprehensive monitoring to navigate the complexities of coexisting chronic pain and mental health challenges.
期刊介绍:
JIN is an international peer-reviewed, open access journal. JIN publishes leading-edge research at the interface of theoretical and experimental neuroscience, focusing across hierarchical levels of brain organization to better understand how diverse functions are integrated. We encourage submissions from scientists of all specialties that relate to brain functioning.